
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Azithromycin for oral suspension, 100 mg/5 mL and 200 mg/5 mL (equiv to Zithromax for oral suspension)
Azithromycin for oral suspension, 100 mg/5 mL and 200 mg/5 mL (equiv to Zithromax for oral suspension)
PLIVA
Meloxicam tablets, 7.5 and 15 mg (equiv to Mobic tablets)
BRECKENRIDGE, COREPHARMA, CARACO, LUPIN LIMITED, MYLAN, WATSON, ZYDUS, ROXANE, TEVA, GLENMARK, PAR, MUTUAL, ACTAVIS TOTOWA, GENPHARM
Estradiol transdermal system, 0.0375 mg/24 hours and 0.06 mg/24 hours (equiv to Climara transdermal system)
MYLAN
Metoprolol extended-release tablets, 25 mg (equiv to Toprol-XL extended-release tablets)
SANDOZ